Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 12Neoplasms 4Recurrence 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Breast Diseases 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Spinal Cord Neoplasms 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Ovarian Neoplasms 1Neurofibromatosis 1 1Neoplasms, Squamous Cell 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Liposarcoma 1Hereditary Sensory and Autonomic Neuropathies 1HR+/HER2- Breast Cancer 1Glioma 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Brain Diseases 1

Interventions

AZD 6244 4trametinib 2omipalisib 1lorlatinib 1encorafenib 1dabrafenib 1binimetinib 1abemaciclib 1Sirolimus 1N-monoacetylcystine 1Lasers, Solid-State 1Lasers 1Inhalation 1Curcumin 1Cetuximab 1Biopsy 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × abemaciclib × 30 days × Clear all
NCT04750928 2026-06-05

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
55 enrolled
CNS

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡